Daiichi's pexidartinib passes Phase III test in TGCT

Daiichi Sankyo Co. Ltd. (Tokyo:4568) said oral pexidartinib (PLX3397) met the primary endpoint of reducing tumor size from baseline to week 25 compared to placebo

Read the full 255 word article

User Sign In